Cell Therapeutics Cuts Expenses As It Transforms Into Commercial Operation
This article was originally published in The Pink Sheet Daily
Executive Summary
CTI will reduce development staff as it shores up its commercial team ahead of Zevalin launch.
You may also be interested in...
Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma
CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.
Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma
CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.
Zevalin Phase II Data Lift Cell Therapeutics
Company submits Xyotax for lung cancer in Europe.